TRIM33 Inhibitors for B Cell Malignancy Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel and potent small molecule compounds that selectively target TRIM33 to treat or prevent malignancies, particularly lineage-specific B cell malignancies, as TRIM33 plays a crucial role in regulating embryonic and adult hematopoiesis and has been implicated as a tumour suppressor in various cancers.
Innovation Solution
Development of compounds of Formula I, or their pharmaceutically acceptable salts or esters, which are capable of inhibiting TRIM33 activity, for use in treating or preventing diseases such as cancer of B cell origin by administering an effective amount to a subject in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule compounds are developed to selectively target TRIM33, then therapeutic efficacy for B cell malignancies is improved, but selectivity over other homologous proteins must be maintained to avoid off-target effects
Solution Approach 1:
The compound is designed to interact with specific local features of the TRIM33 protein structure, particularly the B-box 2 domain, which distinguishes TRIM33 from other TRIM family members. This localized binding approach enables selective inhibition of TRIM33 while sparing homologous proteins with different structural features at this interface.
Solution Approach 2:
The compound structure is optimized by modifying specific parameters including the core scaffold (pyrimidine, pyridine, or triazine ring), substituent groups (R1-R7), and molecular properties to achieve optimal binding affinity for TRIM33. These parameter adjustments allow fine-tuning of selectivity and potency while maintaining the desired therapeutic window.
2Strength
If high potency inhibition of TRIM33 is achieved, then cancer cell killing is enhanced, but normal B cell production may be affected
Solution Approach 1:
The compound achieves partial inhibition of TRIM33 activity at therapeutic doses, which is sufficient to kill cancer cells that are highly dependent on TRIM33 for survival. The inhibition level is controlled to be below thresholds that would significantly impact normal B cell production, exploiting the differential dependency of cancer versus normal cells on TRIM33 function.
Solution Approach 2:
The compound acts as an intermediary that selectively disrupts the TRIM33-SMAD4 interaction in cancer cells, where this interaction is critical for oncogenic signaling. In normal cells, the same interaction is less critical, allowing the compound to preferentially affect cancer cells while sparing normal B cell function.
3Adaptability or versatility
If broad spectrum activity against multiple cancer types is pursued, then versatility is improved, but selectivity for lineage-specific B cell malignancies may be compromised
Solution Approach 1:
The compound is designed to target a conserved functional element of TRIM33 (the B-box 2 domain) that is essential for its tumor suppressor activity across different cancer types. This universal targeting approach enables the compound to be effective against multiple TRIM33-dependent malignancies while maintaining selectivity for TRIM33 over other TRIM family members, achieving both versatility and precision.
Data Source
AI summary
The application relates to a compound of Formula (I):which modulates the activity of TRIM33, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which TRIM33 plays a role.